Type 1 diabetes is one of several autoimmune diseases of unclear etiology in which the discordance rate between identical twins is between 30-40%, even after many years of follow-up. This intermediate discordance rate indicates that there are clearly genetic factors at play in susceptibility to type 1 diabetes, with most genetic contribution coming from the HLA locus. However, this discordance rate also means that other, non-genetic factors, possibly environmental, lead to the development of disease in only one of two genetically identical individuals. No consensus exists on the nature of these putative environmental differences, which are all the more remarkable for occurring in twins that generally share the same intrauterine, family and school environment.
Recent evidence has suggested that the development of certain autoimmune diseases, particularly scleroderma, may be influenced by microchimerism: Both fetomaternal microchimerisms (persistence of fetal cells in the maternal circulation after birth of the child) and maternofetal microchimerism (persistence of maternal cells in the child's circulation for years after birth) have been suggested as creating an abnormal environment that might stimulate the development of autoimmunity in genetically susceptible individuals. The reverse is also possible, i.e., that these abnormal cells may stimulate the immune system in such a way that autoimmunity does not develop.
Identical or monozygotic (MZ) twins who are discordant for type 1 diabetes offer a unique experimental model in which to test the hypothesis that quantitative differences in persistent maternofetal microchimerism influence the development of type 1 diabetes in these genetically susceptible individuals. This study will use pairs of MZ twins discordant for the type 1 diabetes that are already participating in the British Diabetic Twins Study being conducted by Dr. David Leslie at St. Bartholomew's Hospital in London, UK. If the mothers of the twins (both female and male) and offspring of the female twins (only) are available for study, they will be asked to provide a single blood sample (twins, mothers, offspring greater than 12 years of age) or buccal cell sample (offspring less than or equal to 12 years of age) from which DNA will be purified. This is to confirm the origin of the chimeric cells; since cells are passed from the mothers to the offspring during pregnancy, we require (DNA) samples from the mothers of all twins (male and female) who participate in this study. But since the opposite is true, that cells can also be passed from offspring to their mothers during pregnancy, we will require (DNA) samples from the female twins' offspring to determine the true origin of any chimeric cells. The DNA will be used for HLA genotyping to identify nonshared HLA alleles that can be used to develop specific assays for the persistence of maternal DNA in the twins' circulation and quantitative PCR of the mother's genotype in CD3+ cells isolated from the twins. Since trafficking of chimeric cells can be bi-directional, twins who have had offspring of their own may have chimeric cells of both fetal and maternal origin in their circulation. To confirm the origin of the chimeric cells, the blood or buccal cells collected from the offspring of the twins will be genotyped and these compared to the genotypes of the twins' mothers. Blood will be drawn and DNA purified by Dr. Leslie's group in London; the genotyping and quantitative PCR will be performed by Dr. Artlett's group at Thomas Jefferson University, Philadelphia, which has been studying microchimerism since 1998. Results of the study may provide evidence in support of microchimerism as an influential factor in the development of type 1 diabetes. Evidence in support to this concept would be an important addition to the literature on "environmental" factors that influence type 1 diabetes etiology, and also suggest potential immunosuppression or other strategies in type 1 diabetes prevention.
